# A Study of [177Lu]Lu-A9-0631 and [225Ac]Ac-A9-0642 With [68Ga]Ga-A9-6217 or [177Lu]Lu-A9-0631 Imaging in GRPR+ Solid Tumors

> **NCT07661641** · PHASE1 · RECRUITING · sponsor: **Alpha-9 Oncology USA Inc.** · enrollment: 115 (estimated)

## Conditions studied

- Breast Cancer
- Prostate Cancer
- Colorectal Cancer
- GRPR-positive Solid Tumors

## Interventions

- **DIAGNOSTIC_TEST:** [68Ga]Ga-A9-6217
- **DIAGNOSTIC_TEST:** Low dose [177Lu]Lu-A9-0631
- **DRUG:** [177Lu]Lu-A9-0631
- **DRUG:** [225Ac]Ac-A9-0642

## Key facts

- **NCT ID:** NCT07661641
- **Lead sponsor:** Alpha-9 Oncology USA Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-07-01
- **Primary completion:** 2028-12
- **Final completion:** 2029-12
- **Target enrollment:** 115 (ESTIMATED)
- **Last updated:** 2026-09-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07661641

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07661641, "A Study of [177Lu]Lu-A9-0631 and [225Ac]Ac-A9-0642 With [68Ga]Ga-A9-6217 or [177Lu]Lu-A9-0631 Imaging in GRPR+ Solid Tumors". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07661641. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*